Centus Gets European Bevacizumab Approval
Equidacent Rival To Avastin Gains Marketing Authorization
Executive Summary
Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.
You may also be interested in...
Biocon And Viatris Ready To Launch EU Bevacizumab
Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.
Centus Settles US Litigation Over Avastin
Centus Biotherapeutics and Roche’s Genentech have agreed to settle US patent litigation over the biosimilars firm’s FKB238 proposed bevacizumab rival to Avastin.
Mabxience Allies With Zentiva For European Bevacizumab Launch
Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.